

Haycocknema perplexum myositis: the first description of subclinical disease and a proposed distinctive triad to evoke clinical suspicion

Kayla Ward ^{1,2} Anirudh Krishnan,³ Krishnan R Iyengar,⁴ Thomas Robertson,⁴ Richard White,² Ravindra Urkude²

To cite: Ward K, Krishnan A, R Iyengar K, et al. *Haycocknema perplexum* myositis: the first description of subclinical disease and a proposed distinctive triad to evoke clinical suspicion. *BMJ Neurology Open* 2022;**4**:e000290. doi:10.1136/bmjno-2022-000290

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjno-2022-000290>).

Accepted 29 April 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Neurology Department, Gold Coast Hospital and Health Service, Southport, Queensland, Australia

²Neurology Department, Townsville Hospital and Health Service, Townsville, Queensland, Australia

³Division of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia

⁴Pathology, Royal Brisbane Hospital, Herston, Queensland, Australia

Correspondence to

Dr Kayla Ward;
kayla.ward@health.qld.gov.au

ABSTRACT

Introduction *Haycocknema perplexum* is an exceedingly rare cause of parasitic myositis endemic to Australia, more specifically, Tasmania and North Queensland. There is a paucity of literature regarding this diagnosis, with only nine previously described cases.

Diagnosis This report details two cases of biopsy-confirmed *H. perplexum* myositis from Townsville University Hospital and describes the first-ever case of subclinical infection. There is limited known information regarding the *H. perplexum* life cycle and a definitive host which has hindered the development of a non-invasive diagnostic test. A review of the previously described cases has identified the hallmark features of this enigmatic condition: a triad of serological markers including deranged hepatic function, persistent eosinophilia and an elevated creatine kinase.

Conclusions This report aimed to raise awareness of *H. perplexum* myositis and the possibility of subclinical infection, which suggests a protracted disease course. Further research is required to identify a non-invasive diagnostic test, given that early diagnosis and timely initiation of albendazole treatment may drastically limit patient disability.

CASE PRESENTATION

Case 1

A man in his early 40s presented to the neurologist for assessment of musculoskeletal lower back pain following a workplace incident. The patient had no significant medical history and was taking no regular medications. He was found to have an elevated creatine kinase (CK) level of 2300 (normal range 45–250 U/L), mildly deranged liver function tests (LFTs) depicting a transaminitis with an aspartate aminotransferase (AST) of 65 (normal range 10–40 U/L) and alanine aminotransferase (ALT) of 94 (normal range 5–40 U/L), and a persistent eosinophilia between 2 and 3 (normal range 0–0.6 10⁹/L), dating back to 2017. He had previously seen a dermatologist and an immunologist for investigation of his raised eosinophil

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ *Haycocknema perplexum* is an exceedingly rare cause of parasitic myositis endemic to Australia with nine previously reported cases.

WHAT THIS STUDY ADDS

⇒ This report details two cases of biopsy-confirmed *H. perplexum* myositis from Townsville University Hospital and describes the first-ever case of subclinical infection. A review of the previously described cases has identified the hallmark features of this enigmatic condition: a triad of serological markers including deranged hepatic function, persistent eosinophilia and an elevated creatine kinase.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ This report aimed to raise awareness of *H. perplexum* myositis and the possibility of subclinical infection, which suggests a protracted disease course. Further research is required to identify a non-invasive diagnostic test, given that early diagnosis and timely initiation of albendazole treatment may drastically limit patient disability.

count with ultimately no confirmation of the cause for his raised eosinophils. *Strongyloides* is another nematode endemic to North Queensland that causes a peripheral eosinophilia but has no association with myositis or reported muscular invasion; notably, faecal testing was performed in this patient and the results were negative. There were no constitutional symptoms, weakness, muscle pain or bulbar dysfunction. With regard to exposure history, the patient had travelled to Tasmania in his youth but otherwise lived in North Queensland with no overseas travel. He had consumed bush meat a few years previously on a deer hunting trip but otherwise was not an avid bushwalker and had no other history of wildlife exposure. Clinical examination of the cranial nerves and upper and lower limbs




Figure 1 Intracellular parasites with interstitial eosinophilic infiltration evidenced on H&E staining (left; parasite depicted with arrows and eosinophils with arrowheads). MRI shows oedema characterised by high T2 signal in calf muscles bilaterally (signal change indicated with white arrows).

was normal. Repeat review with further serological testing confirmed ongoing raised CK levels despite avoiding strenuous activity over the preceding week. The myositis antibody panel and 3-hydroxy-3-methylglutaryl-CoA reductase antibody tests were negative. Needle electromyography was performed and demonstrated increased spontaneous muscle activity in the lower limb muscles bilaterally. MRI displayed bilateral, symmetric, calf muscle signal change without fatty atrophy. The patient proceeded to have a quadriceps muscle biopsy which confirmed *H. perplexum* myositis, demonstrating the visualisation of the sarcoplasmic parasite in cross-section along with the infiltrate of eosinophils, macrophages and multinucleated giant cells (figure 1). The patient was commenced on oral albendazole 400 mg two times per day and remained asymptomatic with no adverse effects to therapy. Notably, within 1 month of albendazole commencement, there was normalisation of the patient's CK level, LFT derangement and eosinophilia.

Case 2

A woman in her late 20s in her first trimester of pregnancy presented to the neurologist with a 3-year history of progressive symmetrical muscle weakness. The patient was pre-morbidly active and physically fit, her new progressive weakness causing her to withdraw from Muay Thai combat. The patient had no other significant medical history apart from long-standing hepatic dysfunction dating back a decade with a stagnant transaminitis; AST 50–80 (normal range 10–40 U/L) and ALT 45–95 (normal range 5–40 U/L). She had undergone previous extensive gastrointestinal investigations including hepatic biopsy, which failed to yield a diagnosis. The patient was noted by the treating neurologist to have a raised CK level of 3162 (normal range 45–250 U/L), along with an eosinophilia of 1.9 (normal range 0–0.6 × 10⁹/L), which dated back to 2012. There was a history of 5 kg unintentional weight loss over the preceding 6 months with no other constitutional

symptoms. There was no history of bush meat consumption or wildlife exposures. The patient had lived in North Queensland for most of their life with a few years spent in Brisbane and no interstate travel; the only overseas destination was Thailand 3 years ago. Clinical examination revealed normal cranial nerve function with neck flexion weakness and symmetrical proximal upper limb weakness and distal lower limb weakness. The neurological assessment was otherwise normal with no fatigability nor evidence of bulbar dysfunction. Repeat review with serological testing confirmed a persistently raised CK level and eosinophilia. Myositis antibody panel was negative, along with genetic testing for facioscapulohumeral dystrophy, acid maltase testing and a second-generation neuromuscular genetic screening panel. Electrodiagnostic testing, neuroimaging and muscle biopsy were pursued with a conscious decision to avoid steroid use, common practice for empirical treatment of inflammatory myositis. Neurophysiological testing demonstrated evidence of myopathy with diffuse spontaneous activity on needle electromyography (EMG). There were no MRI features of myositis on imaging of the neck and upper limb girdle. Muscle biopsy of the quadriceps was undertaken and the diagnosis of *H. perplexum* myositis was confirmed with visualisation of the nematode on microscopy and evidence of an eosinophilic predominant inflammatory myositis (figure 2). The patient has been commenced on albendazole therapy, which has been deemed safe in her first trimester of pregnancy and at the point of this report's submission remains stable with no adverse effects to therapy.

DISCUSSION

Parasitic myositis is typically reported to be associated with protists, flatworms or roundworms (nematodes).^{1 2} Common nematodes recognised for causing myositis are the *Toxocara* and *Trichinella* species. Recently, *H. perplexum*, a nematode endemic to Australia, has been recognised as an exceedingly rare cause of parasitic myositis, which can be severely disabling and even life-threatening.³ A parasitic myositis is suggested by an appropriate geographical and pathogen exposure history in the presence of a peripheral eosinophilia. Despite some variability in the clinical presentation among the different parasites, a definite diagnosis ultimately depends on the specific pathogen diagnostic test; for example, this would be the demonstration of the characteristic microscopic parasite size and intra-sarcoplasmic location without encysted tissue forms in *H. perplexum* myositis or a positive ELISA for anti-*Trichinella* antibodies in trichinosis. *H. perplexum* myositis poses a significant diagnostic challenge, given the lack of physician awareness and literature surrounding its existence along with the absence of a non-invasive diagnostic test. *H. perplexum* myositis also clinically mimics polymyositis, often resulting in delayed diagnoses and inappropriate initiation of corticosteroid treatment.¹ Steroids propagate parasitic reproduction and result in clinical deterioration.³ This report suggests




Figure 2 Intrasarcoplasmic parasites on H&E, acid phosphatase and PAS staining. Brown haemozoin-like pigment that is sometimes encountered in transverse sections of parasites is visible in the acid phosphatase preparation. PAS, periodic acid–Schiff.

that *H. perplexum* myositis has a subclinical infective state, which suggests a protracted disease course. We aimed to increase awareness of this enigmatic condition to prompt further research into *H. perplexum* with the goal to improve patient outcomes through early diagnosis and timely, appropriate therapy.

H. perplexum is a minute muspiceoid nematode of vertebrates which was first described by Dennett *et al* in 1998, when it was identified as the cause of human parasitic myositis.¹ *H. perplexum* human infection has only ever occurred in Australia, more precisely, in Northern Australia and Tasmania.^{1–9} The zoonotic potential of *H. perplexum* remains a topic of speculation, with some literature supporting the theory that it is acquired through consumption of poorly cooked bush meats, as seen with other parasitic myopathies such as trichinosis and cysticercosis.² Cutaneous penetration has also been considered as a means of human *H. perplexum* contraction, given there is evidence suggesting this mechanism of infection by other muspiceoid in koalas, mice, bats, kangaroos and wallabies.² *H. perplexum* is a suspected human zoonosis, but the natural host remains unknown. *H. perplexum* reproduces efficiently hatching 8–12 infective larvae at a time which invade muscle cells and causes an eosinophilic polymyositis.^{1 2 7} Recent studies have suggested genetic markers with PCR-based DNA sequencing and next-generation




Figure 3 *Haycocknema perplexum* demonstrated on skeletal muscle histology with acid phosphatase and MHC class I IHC. IHC, immunohistochemistry.

DNA sequence analysis to assist with the diagnosis of *H. perplexum*, but speculation remains over the accuracy of this, given the limited case references.^{8 9} The gold standard of diagnosis remains the identification of the *H. perplexum* nematode on muscle biopsy⁸ (figure 3). The biopsy often demonstrates a patchy upregulation of major histocompatibility complex (MHC) class II in myofibre sarcoplasm and sarcolemma, as part of the inflammation. It is thought that the increased acid phosphatase is due to the lysosomes being overwhelmed by parasite proteins. Mild inflammation and eosinophil infiltration may also be seen in conditions such as calpainopathy (LGMD R1). Hence, histological identification of the parasite is crucial. The limited knowledge of the transmission and life cycle of *H. perplexum* hinders the development of a diagnostic serological assay and appropriate infection prevention guidelines, identifying a clear need for further research regarding this curious pathogen.

Although there is limited literature regarding this rare condition, we have reviewed the previous nine cases to determine the typical presentation and clinical features of *H. perplexum* myositis. An insidious onset of slowly progressive diffuse limb weakness is reflected in most cases with bulbar dysfunction presenting as dysarthria and dysphagia seen in 4/11 previously reported cases.^{1–9} Often, these are accompanied by constitutional symptoms, most notably, weight loss up to 18 kg.^{2 6 7} There are four described cases from Tasmania and seven from North Queensland.^{1–3 5–9} Some cases had extensive exposure to animals and wildlife (4/11), and others had consumption of bush meat (4/11), but no consistent exposure has been identified among the patient cohort.^{1–3 5–9} Along with an elevated CK, which was seen in all 11 cases, the other hallmark feature is a persistent eosinophilia that in most cases precedes the diagnosis, some by up to 10 years.^{1–3 5–9} The eosinophilia preceding clinical symptoms supports the suggestion of a subclinical infective period. Eosinophilia was absent in only one described case from

Table 1 Summary of previously published cases of *Haycocknema perplexum* myositis along with the two newly described cases in this report: clinical presentation, laboratory findings and overall patient outcomes

Year	Location	Age, sex	Exposures	Symptoms	Peak CK	Eosinophilia	Steroids	Outcome
1994	Tasmania	33, F	Travel to Northern Territory Extensive animal exposure (botanist) Bush meat consumption	5 years	3294	Yes (0.8)	Yes, deteriorated	Good recovery
1996	Tasmania	48, M	Travel to North Queensland	1.5 years	1586	Yes (2.0)		Ongoing weakness with improved CK (280)
2004	Mackay, North Queensland	61, M	Grew up in Tasmania	3 years of dysphagia and dysarthria with 1 year of limb weakness	1263	Yes for 2 years	Yes - deteriorated	Deceased due to septic complications
2005	Innisfail, North Queensland	23, F	Nil	2 years of progressive weakness, weight loss and dysphagia	1370	Yes (1.1), elevated for prior 10 years	No	Ongoing weakness with improved CK (300) and resolved eosinophilia
2006	Mackay, North Queensland	61, M	Nil	2 years progressive weakness and dysphagia	1230	Yes (1.36), elevated for prior 2 years	No	Improved, ongoing mildly elevated CK (250)
2011	Tasmania	50, M	Animal exposure (avid bush walker) Bush meat consumption	2 years of progressive weakness, weight loss and dysphagia	5700	No	Yes - deteriorated	Improved weakness with persistent CK elevation (470)
2012	Cairns, North Queensland	80, F	Extensive wildlife exposure (wildlife carer) Brief travel to Tasmania	18 months of progressive weakness and weight loss	270	Yes (0.7)	No	Progressive weakness with normalisation of CK and eosinophilia
2015	Townsville, North Queensland	30, M	Nil	2 years of progressive proximal muscle weakness and weight loss	3400	Yes (1.24)	Yes, deteriorated	Good recovery
2015	Tasmania	72, M	Animal exposure (hunter) Bush meat consumption	Years	2082	Yes (2.4)	Yes, deteriorated	Good recovery
2021	Townsville, North Queensland	40s, M	Travel to Tasmania in youth Bush meat consumption	Subclinical	2530	Yes (2.1)	No	Asymptomatic
2021	Townsville, North Queensland	20s, F	Nil	3 years of progressive weakness and weight loss	3162	Yes (1.9)	No	Just commenced therapy

CK, creatine kinase; F, female; M, male.

Tasmania in 2011.⁶ Many cases also reported mild LFT derangements as seen with our patient, although not all case reports commented on the hepatic function and notably the transaminitis seen was disproportionate to the CK level.^{1-3 5-9}

The recommended treatment, based off outcomes in the previous nine cases, is 3 months of albendazole (400 mg two times per day) therapy.^{1-3 5-9} Shorter duration of therapy was shown to result in progressive disease and need for treatment continuation.⁸ In most cases, there is moderate improvement with a persistent weakness likely reflective of the initial severity of infection and degree of established muscle damage and fibrosis. Five of 11 cases were initially treated with steroids for presumed

polymyositis with a notable clinical deterioration and a fatal outcome, as in the case reported by Basuroy *et al.*⁵ This emphasises the importance of increasing awareness of *H. perplexum* myositis to prevent inappropriate steroid initiation and ensure early diagnosis to prevent severe disability.

Ultimately, the diagnosis of *H. perplexum* myositis is confirmed by muscle biopsy with microscopic identification of the non-encysted nematode. Each nematode is approximately 350 µm in length and 20 µm in width with a sharply tapered tail. Female worms within the muscle are often gravid.^{1 2} Table 1 details the clinical presentation, investigations and outcomes of the previous nine biopsy proven cases of *H. perplexum* myositis. This paper

documents the 10th and 11th case and details the first patient with confirmed subclinical *H. perplexum* myositis infection. The inciting process which prompts progression to clinical disease remains unknown.

Based on this case review, we propose that the diagnosis of *H. perplexum* myositis should be investigated in all patients presenting with the distinctive triad of persistent peripheral blood eosinophilia, elevated serum CK and hepatic derangement in the form of transaminitis. Although not specific for parasitic myositis, this proposed diagnostic triad should trigger consideration of diagnosis. There would be a higher clinical suspicion in patients with clinical features suggestive of myositis, including symmetrical weakness and muscle wasting along with bulbar dysfunction and constitutional symptoms and in those with the appropriate geographical exposure. We would also support investigation of asymptomatic patients presenting with features of the triad given our newfound knowledge of subclinical infection with *H. perplexum*, as described in case 1.

CONCLUSIONS

This report details the first-ever subclinical presentation of *H. perplexum* myositis and summarises the limited literature describing this enigmatic condition. We suggest that patients with the appropriate geographical exposure, presenting with the features of the proposed diagnostic triad—persistent eosinophilia, hepatic dysfunction and an elevated CK—be further investigated with muscle imaging and needle EMG in the first instance, even if asymptomatic. If the neuroimaging or electrodiagnostic testing suggests a myopathy, we recommend a muscle biopsy be pursued. Early recognition of *H. perplexum* myositis and initiation of appropriate therapy is essential in limiting ongoing disability. Moving forward, research should be geared towards developing non-invasive diagnostic testing for *H. perplexum* myositis and using it for further epidemiological prevalence studies.

Contributors KW completed the case summary and literature review. AK contributed to the literature review and editing. KRI, TR, RW and RU contributed expert opinion to the discussion and assisted with drafting of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants but was not approved by an ethics committee or an institutional board. The study was deemed minimal risk; it involves information freely available in the public domain from other researchers, and the new data are properly anonymised with retrospective informed consent obtained at the time of original data collection.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Kayla Ward <http://orcid.org/0000-0002-1926-0529>

REFERENCES

- 1 Dennett X, Siejka SJ, Andrews JR, *et al*. Polymyositis caused by a new genus of nematode. *Med J Aust* 1998;168:226–7.
- 2 Spratt DM, ecosystems A. Australian ecosystems, capricious food chains and parasitic consequences for people. *Int J Parasitol* 2005;35:717–24.
- 3 Spratt DM, Beveridge I, Andrews JR, *et al*. Haycocknema perplexum N. G., N. sp. (Nematoda: Robertdollfusidae): an intramyofibre parasite in man. *Syst Parasitol* 1999;43:123–31.
- 4 Eckert J, Ossent P. Haycocknema-like nematodes in muscle fibres of a horse. *Vet Parasitol* 2006;139:256–61.
- 5 Basuroy R, Pennisi R, Robertson T, *et al*. Parasitic myositis in tropical Australia. *Med J Aust* 2008;188:254–6.
- 6 McKelvie P, Reardon K, Bond K, *et al*. A further patient with parasitic myositis due to Haycocknema perplexum, a rare entity. *J Clin Neurosci* 2013;20:1019–22.
- 7 Vos LJ, Robertson T, Binotto E. Haycocknema perplexum: an emerging cause of parasitic myositis in Australia. *Commun Dis Intell Q Rep* 2016;40:E496–9.
- 8 Koehler AV, Spratt DM, Norton R, *et al*. More parasitic myositis cases in humans in Australia, and the definition of genetic markers for the causative agents as a basis for molecular diagnosis. *Infect Genet Evol* 2016;44:69–75.
- 9 Koehler AV, Leung P, McEwan B, *et al*. Using PCR-based sequencing to diagnose Haycocknema perplexum infection in human myositis case, Australia. *Emerg Infect Dis* 2018;24:2368–70.